8-K: KORU Medical Soars with 27% Q3 Revenue Growth, Raises 2025 Outlook

KORU Medical Systems reported strong third-quarter 2025 financial results, including a 27% revenue increase and raised full-year revenue guidance.

Summary

• Net revenues for Q3 2025 reached $10.4 million, a 27.2% increase compared to $8.2 million in Q3 2024.
• Core business net revenues (Domestic and International) grew by 29.7% to $9.8 million.
• International core revenues surged by 229.6% to $3.7 million, driven by strategic market supply and prefilled conversion demands.
• Gross profit increased by 20.8% to $6.3 million, with a gross margin of 60.2%.
• Net loss improved by 51% to ($0.8) million from ($1.6) million in the prior year period.
• Adjusted EBITDA turned positive at $0.09 million, a 121% improvement from ($0.4) million in Q3 2024.
• Ending cash balance was $8.5 million, reflecting $0.4 million in cash generation during the quarter.
• Full-year 2025 revenue guidance was raised to $40.5 $41.0 million, representing 20% 22% year-over-year growth, up from the previous range of $39.5 $40.5 million.
• Full-year gross margin guidance was reiterated at 61% 63%, and positive cash flow from operations for full year 2025 with an ending cash balance greater than $8.2 million was also reiterated.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth, significantly improved its net loss, achieved positive adjusted EBITDA, and raised its full-year revenue guidance. These are strong indicators of positive operational momentum and strategic execution, despite some minor headwinds in domestic core revenue and gross margin.

Positives

• Third quarter 2025 net revenues increased by 27.2% to $10.4 million.
• Core business net revenues (Domestic and International) grew by 29.7% to $9.8 million.
• International core revenues saw a significant increase of 229.6% to $3.7 million.
• Gross profit rose by 20.8% to $6.3 million.
• Net loss improved by 51% to ($0.8) million.
• Achieved positive adjusted EBITDA of $0.09 million, a 121% improvement.
• Generated $0.4 million in cash during the third quarter, ending with $8.5 million in cash.
• Raised full-year 2025 revenue guidance to $40.5 $41.0 million, indicating 20% 22% year-over-year growth.
• Announced two new Pharma Services and Clinical Trials (PST) collaborations, expanding opportunities.
• This was the second consecutive quarter of more than 20% revenue growth.

Negatives

• Domestic core revenues decreased by 5.0% to $6.1 million, primarily due to a US distributor's purchase from an international distributor and inventory reduction.
• Gross margin decreased to 60.2% in Q3 2025 from 63.4% in Q3 2024, driven by higher manufacturing costs, geographic sales mix, and tariff-related charges.
• Pharma Services and Clinical Trials net revenues decreased by 4.4% to $0.6 million, attributed to the staging of NRE work.
• The company still reported a net loss of ($0.8) million, despite significant improvement.

Risks

• Uncertainties associated with SCIg market growth.
• Risks related to prefilled syringe penetration.
• Dependence on plasma supply.
• Uncertainties regarding clinical trial activity and success.
• Risks associated with the approval and commercialization of new drug indications.
• Challenges related to the shift to increased healthcare delivery in the home.
• Impact of new patient diagnoses on demand.
• Variability in customer ordering patterns.
• Potential disruptions from global health crises.
• Threats from innovation and competition.
• Impact of labor and supply price increases.
• Effects of inflationary impacts.
• Availability and cost of labor supply.
• Imposition of tariffs.

Future Outlook

KORU Medical Systems is raising its full-year 2025 net revenues guidance to $40.5 $41.0 million, representing 20% 22% year-over-year growth. The company reiterates its full-year gross margin guidance of 61% 63% and expects positive cash flow from operations for the full year 2025, with an ending cash balance greater than $8.2 million. Management remains focused on accelerating revenue growth, advancing its innovation pipeline, expanding its international footprint, and forming new pharmaceutical collaborations to utilize the Freedom system globally.

Management Comments

• "During the third quarter we continued to make progress on our key strategic goals. We achieved our second consecutive quarter of more than 20% revenue growth, driven by a strong core SCIg business, while delivering positive adjusted EBITDA and cash flow generation."
• "Additionally, we announced two new pharmaceutical collaborations, creating opportunities to reach broader patient populations."
• "As we look ahead, we remain focused on accelerating revenue growth, advancing our innovation pipeline, expanding our international footprint, and forming new pharmaceutical collaborations that utilize the Freedom system to treat more patients on a global scale."

Industry Context

KORU Medical operates in the medical technology sector, specializing in large volume subcutaneous infusion solutions. The company's focus on patient-centric solutions and home administration aligns with broader healthcare trends towards decentralized care and improved quality of life for patients managing chronic conditions. The new Pharma Services and Clinical Trials collaborations indicate a strategic move to integrate its Freedom system into drug development, potentially expanding its market reach within the biopharmaceutical industry. The growth in international core revenues suggests successful expansion in global markets, possibly capitalizing on increasing demand for self-administration solutions.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability metrics (adjusted EBITDA, reduced net loss), and raised full-year guidance, which could lead to increased share value.
• Patients: Potential positive impact through new Pharma Services and Clinical Trials collaborations, expanding access to the Freedom system for new patient populations and drug categories.
• Employees: Positive impact from higher bonus accruals related to increased revenues, indicating potential for performance-based compensation.
• Customers (Distributors): Mixed impact; while international distributors saw increased supply, a US distributor experienced inventory reduction and purchased from an international distributor, indicating shifts in supply chain dynamics.

Next Steps

• Host a live conference call and webcast on November 12, 2025, at 4:30 PM ET to discuss results and provide a corporate update.
• Continue accelerating revenue growth.
• Advance the innovation pipeline.
• Expand the international footprint.
• Form new pharmaceutical collaborations utilizing the Freedom system.
• Gross margin is expected to improve in the fourth quarter of 2025.

Key Dates

Recommendation

KORU Medical Systems has demonstrated robust operational performance with a 27% increase in Q3 revenue and a significant 121% improvement to positive adjusted EBITDA. The company's decision to raise its full-year 2025 revenue guidance signals strong confidence in continued growth. Strategic collaborations in Pharma Services and Clinical Trials are expanding market opportunities, and the reiteration of positive cash flow from operations further strengthens the financial outlook. While domestic core revenue saw a slight dip and gross margin decreased marginally in Q3, the overall trajectory is highly positive, suggesting strong underlying business momentum and potential for future value creation.

Keywords

KORU Medical Systems, Financial Results, Q3 2025, Revenue Growth, Adjusted EBITDA, Medical Technology, Subcutaneous Infusion, Pharma Services, Clinical Trials, Guidance, NASDAQ: KRMD